The use of a tailored protein fusion between epidermal growth factor (EGF; targeting component) and TAU (effector component) resulted in a cytostatic and apoptotic response in epidermal growth factor receptor (EGFR)-positive pancreatic cancer cells [102], a finding confirmed in other models [103]. Here, EGF is linked to pancreatic neoplasm.